Marginal Zone Lymphoma Pipeline Appears Robust With 50+ Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, ' Marginal Zone Lymphoma Pipeline Insight 2025' report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Marginal Zone Lymphoma pipeline landscape. It covers the Marginal Zone Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Marginal Zone Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Marginal Zone Lymphoma Pipeline Report to explore emerging therapies, key Marginal Zone Lymphoma Companies, and future Marginal Zone Lymphoma treatment landscapes @ Marginal Zone Lymphoma Pipeline Outlook Report
Key Takeaways from the Marginal Zone Lymphoma Pipeline Report
In May 2025, BeiGene announced a study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.
In May 2025, Regeneron Pharmaceuticals conducted a study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back after treatment (called "relapsed"), or did not respond to treatment (called "refractory"). FL and MZL are subtypes of Non-Hodgkin 's lymphoma (NHL).
In May 2025, Incyte Corporation organized a study is to evaluate the safety and efficacy of two parsaclisib treatment regimens in participants diagnosed with relapsed or refractory marginal zone lymphoma (MZL) who are naive to or were previously treated with a Bruton's tyrosine kinase (BTK) inhibitor.
In May 2025, Genmab conducted a study will require visits to the sites. During the first month, participants must visit every day or every few days, depending on which trial part the participant enters. After that, participants must visit weekly, every other week, once a month, and once every 2 months, as trial participation ends.
DelveInsight's Marginal Zone Lymphoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Marginal Zone Lymphoma treatment.
The leading Marginal Zone Lymphoma Companies such as Incyte Corporation, HUTCHMED, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc., Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc., Celldex Therapeutics, TG Therapeutics, Inc., VelosBio Inc., Newave Pharmaceutical Inc., Boryung Pharmaceutical Co., Ltd., Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc. and others.
Promising Marginal Zone Lymphoma Therapies such as Pirtobrutinib, Obinutuzumab, Loncastuximab tesirine 150 µg/Kg, Copanlisib, Rituximab, Venetoclax, and others.
Discover how the Marginal Zone Lymphoma treatment paradigm is evolving. Access DelveInsight's in-depth Marginal Zone Lymphoma Pipeline Analysis for a closer look at promising breakthroughs @ Marginal Zone Lymphoma Clinical Trials and Studies
Marginal Zone Lymphoma Emerging Drugs
Tafasitamab: Incyte Corporation
Tafasitamab is an investigational humanized Fc-engineered monoclonal antibody directed against CD19. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb® engineered Fc domain, which is intended to lead to a significant potentiation of antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), thus aiming to improve a key mechanism of tumor cell killing. The therapy is currently in Phase III stage of clinical trial evaluation to treat Marginal Zone Lymphoma.
Amdizalisib (HMPL-689): HUTCHMED
The investigational drug candidate amdizalisib is a novel, selective small molecule inhibitor targeting the isoform phosphoinositide 3'-kinase delta (PI3Kδ), a key component in the B-cell receptor signaling pathway. We have designed amdizalisib with increased PI3Kδ isoform selectivity. Amdizalisib's pharmacokinetic properties have been found to be favorable with good oral absorption, moderate tissue distribution and low clearance in pre-clinical pharmacokinetic studies. Amdizalisib is being investigated in studies in the U.S., Europe, China and Australia in various subtypes of advanced relapsed or refractory non-Hodgkin's lymphoma, including follicular lymphoma and marginal zone lymphoma.
Orelabrutinib: InnoCare Pharma
Orelabrutinib is a small molecule Bruton's tyrosine kinase inhibitor (BTKi) developed for the treatment of cancer and in development for the potential treatment of autoimmune diseases. In the field of oncology, InnoCare received approval for orelabrutinib from the China National Medical Products Administration (NMPA) in two indications: the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)/small lymphocytic lymphoma (R/R SLL), and the treatment of patients with relapsed/refractory mantle cell lymphoma (R/R MCL). Currently, it is in Phase II stage of clinical trial evaluation to treat Marginal Zone Lymphoma (MZL).
EO2463: Enterome
EO2463 is an innovative, off-the-shelf microbiome-peptide based cancer vaccine that combines four microbiome-peptides of B lymphocyte-specific lineage markers. EO2463 is designed to trigger the immune system into recognizing B cells as bacterial (i.e. non-self) and eliciting a targeted cell-killing response. The clinical rationale behind targeting these specific lineage cell markers is to induce the full depletion of malignant B lymphocytes that cause NHL.
The Marginal Zone Lymphoma pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Marginal Zone Lymphoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Marginal Zone Lymphoma Treatment.
Marginal Zone Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Marginal Zone Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Marginal Zone Lymphoma market.
Get a detailed analysis of the latest innovations in the Marginal Zone Lymphoma pipeline. Explore DelveInsight's expert-driven report today! @ Marginal Zone Lymphoma Unmet Needs
Marginal Zone Lymphoma Companies
Incyte Corporation, HUTCHMED, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc., Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc., Celldex Therapeutics, TG Therapeutics, Inc., VelosBio Inc., Newave Pharmaceutical Inc., Boryung Pharmaceutical Co., Ltd., Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc. and others.
Marginal Zone Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
Inhalation
Inhalation/Intravenous/Oral
Intranasal
Intravenous
Intravenous/ Subcutaneous
NA
Oral
Oral/intranasal/subcutaneous
Parenteral
Subcutaneous
Marginal Zone Lymphoma Products have been categorized under various Molecule types such as
Antibody
Antisense oligonucleotides
Immunotherapy
Monoclonal antibody
Peptides
Protein
Recombinant protein
Small molecule
Stem Cell
Vaccine
Download DelveInsight's latest report to gain strategic insights into upcoming Marginal Zone Lymphoma Therapies and key Marginal Zone Lymphoma Developments @ Marginal Zone Lymphoma Market Drivers and Barriers, and Future Perspectives
Scope of the Marginal Zone Lymphoma Pipeline Report
Coverage- Global
Marginal Zone Lymphoma Companies- Incyte Corporation, HUTCHMED, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc., Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc., Celldex Therapeutics, TG Therapeutics, Inc., VelosBio Inc., Newave Pharmaceutical Inc., Boryung Pharmaceutical Co., Ltd., Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc. and others.
Marginal Zone Lymphoma Therapies- Pirtobrutinib, Obinutuzumab, Loncastuximab tesirine 150 µg/Kg, Copanlisib, Rituximab, Venetoclax, and others.
Marginal Zone Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Marginal Zone Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Marginal Zone Lymphoma drug development? Find out in DelveInsight's exclusive Marginal Zone Lymphoma Pipeline Report—access it now! @ Marginal Zone Lymphoma Emerging Drugs and Major Companies
Table of Content
Introduction
Executive Summary
Marginal Zone Lymphoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Marginal Zone Lymphoma – DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Tafasitamab: Incyte Corporation
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Orelabrutinib: InnoCare Pharma
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
EO2463: Enterome
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Marginal Zone Lymphoma Key Companies
Marginal Zone Lymphoma Key Products
Marginal Zone Lymphoma- Unmet Needs
Marginal Zone Lymphoma- Market Drivers and Barriers
Marginal Zone Lymphoma- Future Perspectives and Conclusion
Marginal Zone Lymphoma Analyst Views
Marginal Zone Lymphoma Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
3 hours ago
- Globe and Mail
Prediction: These 2 Stocks Could Beat the Market in the Next Decade
Those concerned about recent market volatility can take comfort in the fact that equity markets will likely deliver competitive returns over the next decade. Selling shares of top companies now may result in lower stock market gains than investors might have otherwise earned over the long term if they had held on. The better strategy is to stick to your holdings and be on the lookout for companies that can perform well, perhaps even better, than the market given enough time. Two stocks that might have what it takes are Roku (NASDAQ: ROKU) and MercadoLibre (NASDAQ: MELI). Here's more on these potential market beaters. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » 1. Roku Although Roku started 2025 strong, its shares have been in free fall for the past few weeks, partly due to somewhat disappointing financial results and guidance. Potential tariff-related headwinds are also not helping. Despite these concerns, the company's financial results remain strong, and its ecosystem continues to grow and strengthen. In the first quarter, Roku's revenue increased by 16% year over year to $1 billion. Streaming hours were 35.8 billion, 5.1 billion more than in the comparable period of the previous fiscal year. As more people spend more time on Roku's platform, the company's ecosystem becomes more valuable to advertisers, a classic example of the network effect. During the first period, Roku's platform revenue, which includes ad-related sales, increased by 17% year over year, compared to 11% year-over-year growth for its device segment, where it reports sales of its namesake streaming devices. Roku remains unprofitable, but it also made some progress on this front in the quarter, reporting a net loss per share of $0.19, which is better than the $0.35 reported in Q1 2024. Roku could feel some volatility in the near term, and the impact of tariffs remains somewhat uncertain. However, Roku has sold its devices at a loss before when faced with the choice. The company prioritizes deepening engagement within its ecosystem -- that's where the long-term opportunity lies. So, if tariffs lead to higher manufacturing costs for its devices, Roku will likely adopt the same strategy as before. Meanwhile, television viewing time is expected to continue shifting away from cable and toward streaming in the long run. And whichever giant in the industry wins the race makes little difference to Roku, which grants its users access to most of the big players in the streaming market. Advertising dollars will follow viewers wherever they go, providing Roku with plenty of revenue growth opportunities. Lastly, Roku's shares look reasonably valued. The company's forward price-to-sales ratio is just 2.3. The official undervalued range starts at 2, but the leader in the connected TV market in North America, even ahead of some tech giants, is worth the slight premium, in my view. Though the stock has dipped in the past few weeks, investors focused on the long game should seriously consider picking up the company's shares and holding on to them for the next decade. 2. MercadoLibre MercadoLibre is the undisputed leader in e-commerce in Latin America. The company has successfully fended off competition from local players and international powerhouses, including Amazon. But MercadoLibre isn't just an e-commerce platform -- it provides a comprehensive suite of services to merchants. The company's fintech platform also looks promising. MercadoLibre's dominance in these markets is leading to strong performances and financial results. The stock has increased by 48% this year. In the first quarter, the company's net revenue increased by 37% year over year to $5.9 billion. MercadoLibre's net income came in at $494 million, up 43.6% compared to the year-ago period. Other important metrics trended up, including gross merchandise volume, fintech monthly active users, and more. Those are the kinds of performances investors are used to with MercadoLibre. It arguably justified its forward price-to-earnings (P/E) ratio of 52.2, nearly twice the 27.9 average for the consumer discretionary sector. Here's the flip side: If MercadoLibre fails to perform in line with market expectations, its shares will drop significantly. Furthermore, although it does business in Latin America and won't suffer directly from the impact of tariffs, general economic instability that could result from President Donald Trump's trade policies would still have an impact on the stock. These are all legitimate concerns, but long-term investors should still consider buying the stock. There is massive whitespace in the e-commerce market in Latin America. Nobody is better positioned to benefit from it. MercadoLibre's revenue and profits should grow rapidly in the next 10 years. Even if the stock experiences a correction due to its valuation, in the long run, it should still outperform the market, just as it has in the past, despite some volatility and steep valuation metrics. MercadoLibre remains a strong candidate to outperform the market through 2035. Should you invest $1,000 in Roku right now? Before you buy stock in Roku, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Roku wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor 's total average return is792% — a market-crushing outperformance compared to171%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025
CTV News
3 hours ago
- CTV News
Alberta resumes U.S. liquor imports
Alberta resumes U.S. liquor imports As CTV Calgary's Tyler Barrow reports, Alberta says it is ready for a renewed trade agreement with the U.S.
CTV News
3 hours ago
- CTV News
Are U.S. tourism efforts to win back Canadian travellers falling flat?
Watch Efforts to lure Canadians to the U.S. may be falling flat as travel to the U.S. fell nearly 13 per cent while travel to non-U.S. destinations rose 19 per cent.
